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Abstract
Myopia, or nearsightedness, is the most common eye
disorder, resulting primarily from excess elongation
of the eye. The etiology of myopia, although known
to be complex, is poorly understood. Here we re-
port the largest ever genome-wide association study
(43,360 participants) on myopia in Europeans. We
performed a survival analysis on age of myopia on-
set and identified 19 significant associations (p <
5 ·10−8), two of which are replications of earlier asso-
ciations with refractive error. These 19 associations
in total explain 2.7% of the variance in myopia age of
onset, and point towards a number of different mech-
anisms behind the development of myopia. One asso-
ciation is in the gene PRSS56, which has previously
been linked to abnormally small eyes; one is in a gene
that forms part of the extracellular matrix (LAMA2 );
two are in or near genes involved in the regenera-
tion of 11-cis-retinal (RGR and RDH5 ); two are near
genes known to be involved in the growth and guid-
ance of retinal ganglion cells (ZIC2, SFRP1 ); and five
are in or near genes involved in neuronal signaling
or development. These novel findings point towards
multiple genetic factors involved in the development
of myopia and suggest that complex interactions be-
tween extracellular matrix remodeling, neuronal de-
velopment, and visual signals from the retina may
underlie the development of myopia in humans.
Author Summary
The genetic basis of myopia, or nearsightedness, is be-
lieved to be complex and affected by multiple genes.
Two genetic association studies have each identified a
single genetic region associated with myopia in Euro-
pean populations. Here we report the results of the
largest ever genetic association study on myopia in
over 40,000 people of European ancestry. We identi-
fied 19 genetic regions significantly associated with
myopia age of onset. Two are replications of the
previously identified associations, and 17 are novel.
Thirteen of the novel associations are in or near
genes implicated in eye development, neuronal devel-
opment and signaling, the visual cycle of the retina,
and general morphology: DLG2, KCNMA1, KCNQ5,
LAMA2, LRRC4C, PRSS56, RBFOX1, RDH5, RGR,
SFRP1, TJP2, ZBTB38, and ZIC2. These findings
point to numerous biological pathways involved in
the development of myopia, and in particular, sug-
gest that early eye and neuronal development may
lead to the eventual development of myopia in hu-
mans.
Introduction
Myopia, or nearsightedness, is the most common eye
disorder worldwide. In the United States, an esti-
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mated 30-40% of the adult population has clinically
relevant myopia (more severe than -1 diopter), and
the prevalence has increased markedly in the last 30
years [1, 2]. Myopia is a refractive error that results
primarily from increased axial length of the eye [3].
The increased physical length of the eye relative to
optical length causes images to be focused in front of
the retina, resulting in blurred vision.
The etiology of myopia is multifactorial [3]. Briefly,
postnatal eye growth is directed by visual stimuli that
evoke a signaling cascade within the eye. This cas-
cade is initiated in the retina and passes through the
choroid to guide remodeling of the sclera (the white
part of the eye) (cf. [4, 5]). Animal models impli-
cate these visually-guided alterations of the scleral
extracellular matrix in the eventual development of
myopia. [4, 6].
In humans the eye typically grows about 5 mm
from birth to age six, during which time vision typ-
ically improves [7]. At age six only about 2% of
children are myopic [7]. Although the eye grows
only 0.5 mm through puberty [8], the incidence of
myopia increases sevenfold [7], peaking between the
ages 9–14 [9]. Myopia developed during childhood or
early adolescence generally worsens throughout ado-
lescence and then stabilizes by age 20. Compared
to myopia that develops in childhood or adolescence,
adult onset myopia tends to be less severe [10–12].
Although epidemiological studies have implicated
numerous environmental factors in the development
of myopia, most notably education, outdoor expo-
sure, reading, and near work [3], it is well established
that genetics plays a substantial role. Twin and sib-
ling studies have provided heritability estimates that
range from 50% to over 90% [13–17]. Children of
myopic parents tend to have longer eyes and are at
increased risk of developing myopia in childhood [18].
Segregation analyses suggest that multiple genes are
involved in the development of myopia [19, 20]. To
date, there have been seven genome-wide associa-
tion studies (GWAS) on myopia or related pheno-
types (pathological myopia, refractive index, and oc-
ular axial length): two in Europeans [21,22] and five
in Asian populations [23–27]. Each of these publica-
tions has identified a different single association with
myopia. In addition there have been several linkage
studies (see [3,28] for reviews) and an exome sequenc-
ing study of severe myopia [29].
In contrast to the previous relatively small (up to
approximately 5,000 initial cases) GWAS that used
degree of refractive error as a quantitative depen-
dent measure, we analyzed data for 43,360 individu-
als from the 23andMe database who reported whether
they had been diagnosed with nearsightedness, and
if so, at what age. We performed a genome-wide sur-
vival analysis on age of onset of myopia, discovering
19 genome-wide significant associations with myopia
age of onset, 17 of which are novel.
Results and Discussion
Participants reported via a web-based questionnaire
whether they had been diagnosed with nearsighted-
ness, and if so, at what age. All participants were
customers of 23andMe and of primarily European
ancestry; no pair was more closely related than at
the level of first cousins. We performed a genome-
wide survival analysis using a Cox proportional haz-
ards model on 43,360 individuals (“discovery set”).
This model assumes that there is an (unknown) base-
line probability of developing myopia at every year
of age. The model then tests whether each single
nucleotide polymorphism (SNP) is associated with a
significantly higher or lower probability of develop-
ing myopia compared to baseline. The Cox model
can be thought of as a generalization of an analysis
of myopia age of onset. In contrast to an analysis of
age of onset, the Cox model allows for the inclusion
of non-myopic controls, resulting in considerably in-
creased statistical power. Analyses controlled for sex
and five principal components of genetic ancestry. An
additional, non-overlapping set of 4,277 participants
who answered a separate question about their use of
corrective eyewear for nearsightedness before the age
of ten were used as a replication set. See Table 1 for
characteristics of the two cohorts.
Table 2 shows the top SNPs for all 27 genetic re-
gions associated with myopia with a p-value smaller
than 10−6. All p-values from the GWAS have been
corrected for the inflation factor of 1.14. A total of
19 of the SNPs cross our threshold for genome-wide
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Number % female Age (SE) Age of onset (SE)
Discovery, myopic 26038 46.1 48.6 (15.7) 16.4 (11.0)
Discovery, not myopic 17322 39.6 49.1 (17.1) —
Replication, myopic at 10 800 45.1 47.7 (14.9) ≤ 10
Replication, not myopic at 10 3477 45.2 50.0 (16.6) —
Table 1: Cohort statistics. Sex, current age, and age of onset for discovery and replication cohorts.
significance (5 · 10−8, see Figure S1). These 19 in-
clude two SNPs previously associated with refractive
error in GWAS of European populations: rs524952
near GJD2 and ACTC1 and rs4778882 near RAS-
GRF1 [21, 22, 30]. p-values genome-wide are shown
in Figure 1; Figure S2 shows the quantile-quantile
plot for the analysis.
Of the 19 SNPs significant in the discovery set,
nine were also significant in the replication set (Ta-
ble 2). As the replication set was small (barely a
tenth the size of the discovery set) and measured age
of onset less exactly, it is not surprising that not
all SNPs replicated. We defined a genetic myopia
propensity score as the number of copies of the risk
alleles across all 19 SNPs identified via the discovery
set. The propensity score showed a strong associa-
tion with early onset myopia (less than 10 years old)
in our replication cohort (p = 6.5 · 10−12, odds ra-
tio 1.08 per risk allele). The top decile of genetic
propensity had 2.54 greater odds of developing my-
opia before the age of 10 than the bottom decile. In
a Cox model fit to the discovery set, the propensity
score explains 2.7% of the total variance. Note that
this estimate may be inflated, as it is calculated on
the discovery population. In this model, someone in
the 90th percentile of risk (a score of 21.4) is nearly
twice as likely to develop myopia by the age of 60 as
someone in the 10th percentile of risk (score of 14.3),
Figure 2.
Of the 17 novel associations, many lie in or near
genes with direct links to processes related to myopia
development. Below, we briefly sketch out possible
connections between these associations and extracel-
lular matrix (ECM) remodeling, the visual cycle, eye
and body growth, retinal neuron development, and
general neuronal development or signaling.
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Figure 2: Estimated survival curves by genetic
propensity score. The genetic propensity score is
computed as the number of risk alleles across the
19 genome-wide significant SNPs. Curves show es-
timated survival probability (i.e., the probability of
not having developed myopia) by age under the fitted
Cox model for the 10th, 50th, and 90th percentiles of
scores (14.3, 17.9, and 21.4, respectively).
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Figure 1: Negative log10 p-values genome wide for myopia. Regions are named with their postulated
candidate gene or genes. p-values under 10−25 have been cutoff (only the LAMA2 region is affected). See
Figure S1 for plots in each region with a significant association.
rsid chr Position Genes MAF r2 allele HR (CI) p-value prepl
rs12193446 6 129820038 LAMA2 0.094 0.991 A/G 0.798 (0.773 – 0.823) 1 · 10−42 4.9 · 10−4
rs11602008 11 40149305 LRRC4C 0.160 0.887 A/T 1.149 (1.121 – 1.177) 1.3 · 10−24 0.012
rs17648524 16 7459683 RBFOX1 0.364 0.974 G/C 1.095 (1.075 – 1.114) 3.5 · 10−20 0.27
rs3138142 12 56115585 RDH5 0.218 0.817 C/T 0.892 (0.872 – 0.913) 1.2 · 10−19 0.0074
chr8:60178580 8 60178580 TOX/CA8 0.358 0.970 C/G 0.917 (0.900 – 0.934) 2.6 · 10−18 0.26
rs7744813 6 73643289 KCNQ5 0.405 0.955 A/C 0.920 (0.904 – 0.937) 1.7 · 10−17 0.0016
rs524952 15 35005886 GOLGA8B/GJD2 0.468 0.980 T/A 1.078 (1.059 – 1.097) 3.3 · 10−15 0.0019
rs2137277 8 40734662 SFRP1 0.189 0.922 A/G 0.908 (0.887 – 0.929) 1.8 · 10−14 0.52
rs1550094 2 233385396 PRSS56 0.306 0.963 A/G 1.077 (1.057 – 1.098) 4.9 · 10−13 0.019
rs11681122 2 146786063 PABPCP2 0.425 0.940 A/G 0.937 (0.920 – 0.954) 3.6 · 10−11 0.085
rs7624084 3 141093285 ZBTB38 0.435 0.961 T/C 0.942 (0.925 – 0.959) 3.8 · 10−10 0.19
rs1898585 2 178660450 PDE11A 0.163 0.942 C/T 1.085 (1.059 – 1.111) 4.9 · 10−10 0.011
rs2908972 17 11407259 SHISA6 0.397 0.970 T/A 1.060 (1.042 – 1.079) 1.7 · 10−9 0.053
rs6480859 10 79081948 KCNMA1 0.363 0.987 C/T 1.060 (1.042 – 1.079) 2.0 · 10−9 0.82
rs10736767 11 84637065 DLG2 0.451 0.996 A/C 1.058 (1.040 – 1.077) 2.2 · 10−9 0.53
rs11145746 9 71834380 TJP2 0.198 0.886 G/A 1.076 (1.052 – 1.100) 4.2 · 10−9 0.77
rs4291789 13 100672921 ZIC2 0.326 0.724 C/G 1.070 (1.048 – 1.093) 6 · 10−9 2.2 · 10−4
rs4778882 15 79382019 RASGRF1 0.399 0.951 A/G 1.059 (1.040 – 1.078) 6.1 · 10−9 0.017
rs745480 10 85986554 RGR 0.474 0.975 C/G 1.056 (1.038 – 1.075) 8 · 10−9 0.32
rs5022942 4 81959966 BMP3 0.229 0.991 G/A 1.063 (1.041 – 1.085) 5.9 · 10−8 0.21
rs9365619 6 164251746 QKI 0.457 0.999 C/A 1.051 (1.033 – 1.069) 1 · 10−7 0.097
rs1031004 4 80516849 ANTXR2 0.261 0.983 T/A 1.058 (1.037 – 1.079) 1.5 · 10−7 0.62
rs17428076 2 172851936 HAT1/MAP1D 0.236 0.985 C/G 0.943 (0.924 – 0.963) 1.6 · 10−7 0.18
chr14:54413001 14 54413001 BMP4 0.489 0.930 G/C 0.952 (0.935 – 0.969) 4.6 · 10−7 0.38
rs7272323 20 4756691 PRND/RASSF2 0.409 0.955 C/G 1.050 (1.031 – 1.068) 7 · 10−7 0.015
chr11:65348347 11 65348347 EHBP1L1 0.017 0.558 G/A 0.781 (0.711 – 0.858) 7.9 · 10−7 0.97
rs55819392 21 40038207 ERG/ETS2 0.259 0.987 G/A 0.949 (0.930 – 0.968) 9.2 · 10−7 0.014
Table 2: Index SNPs for regions with p < 10−6. Index SNPs for regions with (λ-corrected) p-values
under 10−6. Positions and alleles are given relative to the positive strand of build 37 of the human genome;
alleles are listed as major/minor. The listed genes are the postulated candidate gene in each region. r2 is the
estimated imputation accuracy; HR is the hazard ratio per copy of the minor allele; p-value is the p-value
in the discovery cohort; prepl is the p-value in the replication cohort.
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Extracellular Matrix Remodeling
The strongest association is a SNP in an intron
of LAMA2 (laminin, alpha 2 subunit, rs12193446,
p = 1.0 · 10−42, hazard ratio (HR) 0.80). Laminins
are extracellular structural proteins that are integral
parts of the ECM. Changes in the composition of the
ECM of the sclera have been shown to alter the ax-
ial length of the eye [5]. Laminins play a role in the
development and maintenance of different eye struc-
tures [31, 32]. The laminin alpha 2 chain is found in
the extraocular muscles during development [31], and
may act as an adhesive substrate and possibly a guid-
ance cue for retinal ganglion cell growth cones [33].
We also found a suggestive association related to
laminin (rs1031004, p = 1.5 · 10−7, HR=1.06) 312
kb upstream of ANTXR2 (anthrax toxin receptor 2).
ANTXR2 binds laminin and possibly collagen type
IV [34] and thus may also be involved in extracellu-
lar matrix remodeling.
The Visual Cycle
Two of the novel associations are in or near genes in-
volved in the regeneration of 11-cis-retinal, the light
sensitive component of photoreceptors; this regener-
ation is commonly referred to as the visual cycle of
the retina. These associations are with rs3138142,
p = 1.2 · 10−19, HR=0.89 in RDH5 (retinol dehydro-
genase 5 (11-cis/9-cis)) and rs745480 (p = 8.0 · 10−9,
HR=1.06), a SNP 18 kb upstream of RGR, which
encodes the retinal G protein-coupled receptor. The
SNP rs3138142 is a synonymous change in RDH5.
It has been linked to RDH5 expression [35, 36], and
it is part of an Nr2f2 (nuclear receptor subfamily 2,
group F, member 2) transcription factor binding mo-
tif in mouse [37,38]. Both RDH5 and RGR play cru-
cial roles in the regeneration of 11-cis retinal in the
retinal pigment epithelium (RPE) [39]. Mutations in
RDH5 have been linked with fundus albipunctatus, a
rare form of congenital stationary night blindness (for
a recent review, see [40]) and progressive cone dys-
trophy [41], and mutations in RGR have been linked
with autosomal recessive and autosomal dominant re-
tinitis pigmentosa [42,43].
We also identified an association within another
gene that functions in the RPE: rs7744813 (p =
1.7 · 10−17, HR=0.92), a SNP in KCNQ5 (potassium
voltage-gated channel, KQT-like subfamily, member
5). KCNQ5 encodes a potassium channel found in
the RPE and neural retina. These channels are be-
lieved to contribute to ion flow across the RPE [44,45]
and to affect the function of cone and rod photore-
ceptors [45].
Eye and Body Growth
Three of our associations show possible links to eye
or overall morphology. The first is a missense muta-
tion in PRSS56 (A224T, rs1550094, p = 4.9 · 10−13,
HR=1.08). Other mutations in PRSS56 have been
shown to cause strikingly small eyes with severe de-
creases in axial length [46–48]. Two other associ-
ated SNPs are in linkage disequilibrium with SNPs
previously associated with height: rs10113215 (p =
2.6 · 10−18, HR=0.92), near TOX and CA8 (thymus
high mobility group box protein; carbonic anhydrase
VIII), and rs7624084 (p = 3.8·10−10, HR=0.94), near
ZBTB38 (zinc finger and BTB domain-containing
protein 38). The SNPs rs10113215 and rs7624084 are
in linkage disequilibrium (LD) with rs6569648 and
rs6763931, respectively (r2 > 0.6 and r2 > 0.8); both
of which have been associated with height [49,50].
Retinal Ganglion Cell Projections
Two of the novel associations are near genes that af-
fect the outgrowth of retinal ganglion neurons during
development. The first is rs4291789 (p = 6.0 · 10−9,
HR=1.07), which lies 34 kb downstream of ZIC2 (Zic
family member 2). ZIC2 regulates two independent
parts of ipsilateral retinal ganglion cell development:
axon repulsion at the optic chiasm midline [51, 52],
and organization of the axonal projections at their
final targets in the brain [53].
The second, rs2137277 (p = 1.8 · 10−14, HR=0.91),
is a variant in ZMAT4 (zinc finger, matrin-type 4).
ZMAT4 has no known link to vision, but this vari-
ant also lies 385 kb downstream of SFRP1 (secreted
frizzled-related protein 1). SFRP1 is involved in
the differentiation of the optic cup from the neural
retina [54], retinal neurogenesis [55], the development
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and function of photoreceptor cells [56, 57], and the
growth of retinal ganglion cells [58].
Neuronal Signaling and Development
Finally, we found five associations with SNPs in
genes involved in neuronal development and signal-
ing, but without a known role in vision develop-
ment or the vision cycle: in KCNMA1 (potassium
large conductance calcium-activated channel, sub-
family M, alpha member 1; rs6480859, p = 2.0 ·10−9,
HR=1.06); in RBFOX1 (RNA binding protein, fox-
1 homolog; rs17648524, p = 3.5 · 10−20, HR=1.10);
in LRRC4C, leucine rich repeating region contain-
ing 4C, also known as NGL-1 (rs11602008, p =
1.3·10−24, HR=1.15); in DLG2 (discs, large homolog
2; rs10736767, p = 2.2·10−9, HR=1.06); and in TJP2
(tight junction protein 2; rs11145746, p = 4.2 · 10−9,
HR=1.08).
KCNMA1 encodes the pore-forming alpha subunit
of a MaxiK channel, a family of large conductance,
voltage and calcium-sensitive potassium channels in-
volved in the control of smooth muscle and neuronal
excitation. RBFOX1 belongs to a family of RNA
binding proteins that regulates the alternative splic-
ing of several neuronal transcripts implicated in neu-
ronal development and maturation [59]. LRRC4C
encodes a binding partner for netrin G1 and promotes
the outgrowth of thalamocortical axons [60]. DLG2
plays a critical role in the formation and regulation of
protein scaffolding at postsynaptic sites [61]. TJP2
has been linked with hearing loss: its duplication and
subsequent overexpression are found in adult-onset
progressive nonsyndromic hearing loss [62].
Conclusion
This study represents the largest GWAS on myopia
in Europeans to date. This cohort of 43,360 indi-
viduals led to the discovery of 17 novel associations
as well as replication of the two previously reported
associations in Europeans. In contrast to the earlier
studies that used refractive error as a quantitative
outcome, we used a Cox proportional hazards model
with age of onset of myopia as our major endpoint.
This model yielded greater statistical power than a
simple case-control study of myopia. Of the 19 signif-
icant SNPs found using this model, all but one had
smaller p-values when a hazards model was employed,
and only 13 would be genome-wide significant using a
case-control analysis on the same dataset (Table S1).
The proportional hazards model assumes that each
SNP has a constant effect on the hazard of develop-
ing myopia at any age. When we tested the validity
of this assumption for the 19 significant SNPs, five
showed evidence of different effects at different ages
(Table S2). While this violation should not lead to
overly small p-values for these SNPs in the GWAS,
it does make risk prediction based on these results
less straightforward. These age dependent hazards
suggest that different biological processes may affect
the development of myopia at different ages. For ex-
ample, rs12193446 in LAMA2 shows a large effect
on myopia hazard at an early age, peaking around
11 years, and then a null or even negative effect on
hazard after the age of 30; other SNPs show different
patterns of effect as a function of age (Figure S3).
Our findings further suggest that there may be
somewhat different genetic factors underlying myopia
age of onset and refractive error. Because adult on-
set myopia tends to be less severe than myopia de-
veloped in childhood or adolescence [10–12], age of
onset is likely correlated with refractive error, but
it is not known how strongly. Many of our associ-
ations showed a stronger signal than the two asso-
ciations near GJD2 and near RASGRF1 previously
linked with refractive error in Europeans. Notably,
the latter association, near RASGRF1, also failed to
replicate in a recent meta-analysis [30]. The fact that
many of our associations with strong effects on age
of onset have not shown up in previous refractive er-
ror GWAS implies that some genetic factors may af-
fect the age of onset independent of eventual severity,
and that the strength of different genetic associations
with myopia may depend on the specific phenotype
under study.
We also note that our phenotype was based on
participants’ reports rather than clinical assessments.
Although in theory errors in recall could have affected
our results, we expect that the vast majority of peo-
ple are able to recall when they first wore glasses with
at most a few years of error.
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The five associations previously reported in patho-
logical myopia or refractive error GWAS in Asian
populations [23–27] show no overlap with the signifi-
cant or suggestive regions found here. Nor did we find
an association with the ZNF644 locus that was iden-
tified as the site of high-penetrance, autosomal dom-
inant mutations in Han Chinese families with appar-
ent monogenic inheritance of high-grade myopia [29].
This lack of overlap is further evidence that the ge-
netic factors involved in myopia differ across popula-
tions.
Our identification of 17 novel genetic associations
suggests several novel genetic pathways in the de-
velopment of human myopia. These findings aug-
ment existing research on the development of myopia,
which to date has been studied primarily in animal
models of artificially induced myopia. Some of the as-
sociations are consistent with the current view, based
largely on animal models, that a visually-triggered
signaling cascade from the retina ultimately guides
the scleral remodeling that leads to eye growth, and
that the RPE plays a key role in this process [4].
A number of the novel associations point to the po-
tential importance of early neuronal development in
the eventual development of myopia, particularly the
growth and topographical organization of retinal gan-
glion cells. These associations suggest that early neu-
ronal development may also contribute to future re-
fractive errors. We expect that these findings will
drive new research into the complex etiology of my-
opia.
Methods
Human Subjects
All participants were drawn from the customer base
of 23andMe, Inc., a consumer genetics company. This
cohort has been described in detail previously [63,64].
Participants provided informed consent and partici-
pated in the research online, under a protocol ap-
proved by the external AAHRPP-accredited IRB,
Ethical & Independent Review Services (E&I Re-
view).
Phenotype data
Participants in the discovery cohort were asked on-
line as part of a medical history questionnaire: “Have
you ever been diagnosed by a doctor with any of the
following vision conditions?: Nearsightedness (near
objects are clear, far objects are blurry) (Yes/No/I
don’t know)”. If they answered “yes”, they were
asked, “At what age were you first diagnosed with
nearsightedness (near objects are clear, far objects
are blurry)? Your best guess is fine.” Those report-
ing an age of onset outside of the range 0–100 were
removed from analysis. All participants also reported
current age.
The replication cohort consisted of 23andMe cus-
tomers who were not part of the discovery cohort
(i.e., they didn’t provide a nearsightedness diagno-
sis). They answered a single question “Did you wear
glasses or other corrective eyewear for nearsighted-
ness before the age of 10? (Yes/No/I’m not sure)”.
Genotyping and imputation
Participants were genotyped and additional SNP
genotypes were imputed against the August 2010 re-
lease of the 1000 genomes data as described previ-
ously [65]. Briefly, they were genotyped on at least
one of three genotyping platforms, two based on
the Illumina HumanHap550+ BeadChip, the third
based on the Illumina Human OmniExpress+ Bead-
Chip. The platforms included assays for 586,916,
584,942, and 1,008,948 SNPs respectively. Geno-
types for a total of 11,914,767 SNPs were imputed
in batches of roughly 10,000 individuals, grouped by
genotyping platform. Of these, 7,087,609 met our
criteria of 0.005 minor allele frequency, average r2
across batches of at least 0.5, and minimum r2 across
batches of at least 0.3. (The minimum r2 requirement
was added to filter out SNPs that imputed poorly in
the batches consisting of the less dense platform.)
Statistical analysis
In order to minimize population substructure while
maximizing statistical power, the study was limited
to individuals with European ancestry. Ancestry was
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inferred from the genome-wide genotype data, and
principal component analysis was performed as in [63,
66]. No two participants shared more than 700 cM of
DNA identical by descent (IBD, approximately the
lower end of sharing between a pair of first cousins).
IBD was calculated using the methods described in
[67].
For the survival analysis, let the hazard function
h(t) be the rate of developing myopia at time t. Then
the Cox proportional hazards model is
log h(t) = α(t) + βgG+ βsS +
5∑
i=1
βpciPCi
for an arbitrary baseline hazard function α(t) and
covariates G (genotype), S (sex) and PC1, . . . , PC5
(projections onto principal components). G was
coded as a dosage from 0–2 as the estimated num-
ber of minor alleles present.
For each SNP, we fit a Cox proportional hazards
model using R [68] and computed a p-value using
a likelihood ratio test for the genotype term. All
SNPs with p-values under 5 ·10−8 after genomic con-
trol correction were considered genome-wide signif-
icant. The hazard ratio (HR) reported throughout
can be interpreted as the multiplicative change in the
rate of onset of myopia per copy of the minor allele
(e.g., eβg ). To test the proportional hazards assump-
tion, we tested for independence of the scaled Schoen-
feld residuals for each significant SNP and time us-
ing cox.zph (Table S2). Replication p-values in Ta-
ble 2 are one-sided p-values for a logistic regression
model controlling for age, sex, and five principal com-
ponents.
For Figure 2, we computed a myopia propensity
score for each individual as the (estimated) number
of risk alleles among the 19 genome-wide significant
SNPs. We then fit a Cox model including that score,
sex, and five principal components. To estimate pro-
portion variance explained for this model, we used
a pseudo-r2 using likelihoods (similar to the Nagelk-
erke pseudo r2 for logistic regression). That is, we
calculated the variance explained as
r2 =
1− LnL0
1− 1nL0
,
where L0 is the null likelihood and L the likelihood
for the full model. This is one of several methods used
to compute variance explained for Cox proportional
hazards models [69].
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Figure S1: Region plots for genome-wide significant associations Colors depict the squared correlation
(r2) of each SNP with the most associated SNP (shown in purple). Gray indicates SNPs for which r2
information was missing.
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Figure S1: Region plots for genome-wide significant associations Colors depict the squared correlation
(r2) of each SNP with the most associated SNP (shown in purple). Gray indicates SNPs for which r2
information was missing.
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Figure S1: Region plots for genome-wide significant associations Colors depict the squared correlation
(r2) of each SNP with the most associated SNP (shown in purple). Gray indicates SNPs for which r2
information was missing.
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Figure S1: Region plots for genome-wide significant associations Colors depict the squared correlation
(r2) of each SNP with the most associated SNP (shown in purple). Gray indicates SNPs for which r2
information was missing.
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Figure S1: Region plots for genome-wide significant associations Colors depict the squared correlation
(r2) of each SNP with the most associated SNP (shown in purple). Gray indicates SNPs for which r2
information was missing.
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Figure S2: Quantile-quantile plot for myopia survival analysis Actual (λ-corrected) p-values versus
the null.
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(d) chr8:60178580, p = 2.4 · 10−4
Figure S3: Smoothed log-hazard ratios as a function of age for four representative SNPs In each
plot, the straight line shows the estimated log-hazard ratio (beta) for each SNP in the proportional hazards
model. The solid curve is a spline fit to beta estimated at different ages; the dotted curves are approximate
95% confidence intervals. The p-value in each caption is the result of a test of the proportional hazards
assumption. The sign of all coefficients has been made positive for ease of comparison (so (a), (c), and (d)
are flipped relative to the main text). Note that among the examples here, only (c) shows no evidence of
deviation from the proportional hazards assumption.
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Table S1: p-values for survival and case-control analyses
SNP p (survival) p (case-control)
rs12193446 1 · 10−42 8.1 · 10−33
rs11602008 1.3 · 10−24 1.2 · 10−20
rs17648524 3.5 · 10−20 2.2 · 10−17
rs3138142 1.2 · 10−19 7.9 · 10−20
chr8:60178580 2.6 · 10−18 2.1 · 10−14
rs7744813 1.7 · 10−17 3 · 10−15
rs524952 3.3 · 10−15 8.8 · 10−12
rs2137277 1.8 · 10−14 4.8 · 10−11
rs1550094 4.9 · 10−13 1.7 · 10−10
rs11681122 3.6 · 10−11 1.6 · 10−10
rs7624084 3.8 · 10−10 1.3 · 10−8
rs1898585 4.9 · 10−10 7.9 · 10−8
rs2908972 1.7 · 10−9 8.3 · 10−8
rs6480859 2.0 · 10−9 7.9 · 10−8
rs10736767 2.2 · 10−9 1.6 · 10−8
rs11145746 4.2 · 10−9 3.1 · 10−7
rs4291789 6 · 10−9 6 · 10−7
rs4778882 6.1 · 10−9 3 · 10−8
rs745480 8 · 10−9 8.6 · 10−8
rs5022942 5.9 · 10−8 1 · 10−6
rs9365619 1 · 10−7 2.9 · 10−7
rs1031004 1.5 · 10−7 1.7 · 10−7
rs17428076 1.6 · 10−7 2.8 · 10−6
chr14:54413001 4.6 · 10−7 2.8 · 10−6
rs7272323 7 · 10−7 1.2 · 10−5
chr11:65348347 7.9 · 10−7 6.2 · 10−7
rs55819392 9.2 · 10−7 1.7 · 10−6
p-values for SNPs in the survival analysis used in the paper as well as in a case-control logistic regression
on the same set of individuals. The survival analysis gives a smaller p-value for all but 1 SNP (rs3138142)
and has 19 genome-wide significant (p < 5 · 10−8) as compared to 13 for the case-control. p-values in both
cases are adjusted for the genomic control inflation factor of 1.14.
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Table S2: Tests of deviation from the proportional hazards assumption
SNP p-value
rs12193446 5.5 · 10−9
rs11602008 0.64
rs17648524 0.0011
rs3138142 0.97
chr8:60178580 2.4 · 10−4
rs7744813 0.063
rs524952 3.9 · 10−4
rs2137277 0.016
rs1550094 0.0026
rs11681122 0.59
rs7624084 0.32
rs1898585 0.0059
rs2908972 0.013
rs6480859 0.10
rs10736767 0.093
rs11145746 0.0038
rs4291789 0.37
rs4778882 0.34
rs745480 0.035
p-values for significant SNPs for deviation from the proportional hazards assumption in the Cox model.
For each SNP, we fit a Cox proportional hazards model including the SNP, sex, and five principal
components as predictors, and then tested for independence of the scaled Schoenfeld residuals with time.
Bold SNPs deviate significantly from this assumption after correction for 19 tests. Plots for four example
SNPs are shown in Figure S3.
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